Steiner and colleagues demonstrated that using bindarit, as a CCL2 synthesis inhibitor, leads to suppression of polyomavirus-related breast cancer development by down-regulation of CCL2 in the tumor tissue, but not in the plasma [55]. This evidence concerns the gene CCL2 and breast carcinoma.